Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Innate Pharma Receives Development Milestone Payment From BMS | Contract Pharma

What are you searching for?

Sign in
Breaking News

Innate Pharma Receives Development Milestone Payment From BMS

Triggered by dosing of a first patient in a Phase II trial of lirilumab

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Innate Pharma SA has received a $5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licensing agreement.

This payment was triggered by the dosing of a first patient in a Phase II trial of lirilumab in combination with rituximab in patients with relapsed/refractory or high-risk untreated chronic lymphocytic leukemia.

Herve Brailly, chief executive officer and co-founder of Innate Pharma, said, “This milestone marks the start of a new Phase II trial of lirilumab in hemato-oncology outside of acute meloid leukemia. We are pleased with the broad clinical program for lirilumab, and expect that results will begin to be delivered in 2016.”

In total, 6 trials are currently being performed with lirilumab, testing a range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, checkpoint inhibitors and chemotherapy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics